These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11236218)

  • 21. Quantitative analysis of eyelash lengthening following topical latanoprost therapy.
    Sugimoto M; Sugimoto M; Uji Y
    Can J Ophthalmol; 2002 Oct; 37(6):342-5. PubMed ID: 12422916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Latanoprost and pigmentation.
    Grierson I; Jonsson M; Cracknell K
    Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latanoprost-related transient incontinence.
    Raja V; Sandanshiv P; Asghar M; Moriarty B
    Clin Exp Ophthalmol; 2007; 35(4):389-90. PubMed ID: 17539800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertrichosis of the upper cheek area associated with travoprost treatment of glaucoma.
    Ortiz-Perez S; Olver JM
    Ophthalmic Plast Reconstr Surg; 2010; 26(5):376-7. PubMed ID: 20622697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adverse reaction after use of latanoprost in Japanese glaucoma patients].
    Inoue K; Wakakura M; Inoue J; Matsuo H; Hara T; Tomita G
    Nippon Ganka Gakkai Zasshi; 2006 Aug; 110(8):581-7. PubMed ID: 16972649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin graft hypertrichosis associated with prostaglandin analog in the treatment of glaucoma.
    Shafi F; Madge SN
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):e3-5. PubMed ID: 23811595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.
    Tauchi M; Fuchs TA; Kellenberger AJ; Woodward DF; Paus R; Lütjen-Drecoll E
    Br J Dermatol; 2010 Jun; 162(6):1186-97. PubMed ID: 20346040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows.
    Faghihi G; Andalib F; Asilian A
    Eur J Dermatol; 2009; 19(6):586-7. PubMed ID: 19620039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
    Alm A; Grunden JW; Kwok KK
    J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darkening of eyelashes in a patient treated with latanoprost.
    Reynolds A; Murray PI; Colloby PS
    Eye (Lond); 1998; 12 ( Pt 4)():741-3. PubMed ID: 9850277
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
    Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
    Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trichiasis associated with prostaglandin analog use.
    Bearden W; Anderson R
    Ophthalmic Plast Reconstr Surg; 2004 Jul; 20(4):320-2. PubMed ID: 15266150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
    Kobayashi H; Kobayashi K
    J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic side effects of topical latanoprost.
    Rajan MS; Syam P; Liu C
    Eye (Lond); 2003 Apr; 17(3):442-4. PubMed ID: 12724721
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased eyelid pigmentation associated with use of latanoprost.
    Kook MS; Lee K
    Am J Ophthalmol; 2000 Jun; 129(6):804-6. PubMed ID: 10926995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
    Friström B; Uusitalo H
    Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
    Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
    Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
    Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extensive facial skin pigmentation after latanoprost treatment.
    Chien KH; Lu DW; Chen JT
    Cutan Ocul Toxicol; 2009; 28(4):185-7. PubMed ID: 19888889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.